These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 12060436)

  • 1. Tolterodine: as effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder.
    Lee JG; Hong JY; Choo MS; Kwon HY; Chung DY; Lee KS; Lee JY; Lee T
    Int J Urol; 2002 May; 9(5):247-52. PubMed ID: 12060436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
    D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R
    J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nocturia, nocturnal incontinence prevalence, and response to anticholinergic and behavioral therapy.
    Fitzgerald MP; Lemack G; Wheeler T; Litman HJ;
    Int Urogynecol J Pelvic Floor Dysfunct; 2008 Nov; 19(11):1545-50. PubMed ID: 18704249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxybutynin-associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment.
    Chancellor MB; Lucioni A; Staskin D
    Urology; 2024 Apr; 186():123-129. PubMed ID: 38296001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial Comment on " Oxybutynin-associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment".
    Van Kuiken ME
    Urology; 2024 Apr; 186():130. PubMed ID: 38290666
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical utility of transdermal delivery of oxybutynin gel via a metered-dose pump in the management of overactive bladder.
    Wagg A
    Res Rep Urol; 2012; 4():57-64. PubMed ID: 24199182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Updated Structure of Oxybutynin Hydrochloride.
    Lin J; Bu G; Unge J; Gonen T
    bioRxiv; 2024 Jun; ():. PubMed ID: 38895300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative adherence to oxybutynin or tolterodine among older patients.
    Gomes T; Juurlink D; Mamdani M
    Eur J Clin Pharmacol; 2012 Feb; ():. PubMed ID: 22315150
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of extended release tolterodine used for overactive bladder treatment on female sexual function.
    Zachariou A; Filiponi M
    Int Braz J Urol; 2017; 43(4):713-720. PubMed ID: 28199076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effectiveness of Anticholinergic Therapy for Overactive Bladders: Systematic Review and Meta-Analysis.
    Fonseca AM; Meinberg MF; Monteiro MV; Roque M; Haddad JM; Castro RA
    Rev Bras Ginecol Obstet; 2016 Nov; 38(11):564-575. PubMed ID: 28008590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Voiding Disorders In Children.
    Kanitkar M; Joshi DP; Chander V; Puri B
    Med J Armed Forces India; 2004 Oct; 60(4):367-71. PubMed ID: 27407676
    [No Abstract]   [Full Text] [Related]  

  • 12. Overactive bladder - 18 years - Part II.
    Truzzi JC; Gomes CM; Bezerra CA; Plata IM; Campos J; Garrido GL; Almeida FG; Averbeck MA; Fornari A; Salazar A; Dell'Oro A; Cintra C; Sacomani CA; Tapia JP; Brambila E; Longo EM; Rocha FT; Coutinho F; Favre G; Garcia JA; Castano J; Reyes M; Leyton RE; Ferreira RS; Duran S; Lopez V; Reges R
    Int Braz J Urol; 2016; 42(2):199-214. PubMed ID: 27176185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerance of bladder antispasmodics in children with urinary incontinence: An observational study from North India.
    Bansal V; Medhi B; Prakash O; Kaur B; Narasimhan K
    Indian J Pharmacol; 2011 Nov; 43(6):744-5. PubMed ID: 22144795
    [No Abstract]   [Full Text] [Related]  

  • 14. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach.
    Kessler TM; Bachmann LM; Minder C; Löhrer D; Umbehr M; Schünemann HJ; Kessels AG
    PLoS One; 2011 Feb; 6(2):e16718. PubMed ID: 21373193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agents for treatment of overactive bladder: a therapeutic class review.
    Hesch K
    Proc (Bayl Univ Med Cent); 2007 Jul; 20(3):307-14. PubMed ID: 17637888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy for overactive bladder: an evidence-based approach to selecting an antimuscarinic agent.
    Appell RA
    Drugs; 2006; 66(10):1361-70. PubMed ID: 16903770
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.